KYTX · Kyverna Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| R&D | $30.07M | - | $30.46M | $35.82M | $37.43M | - | $13.64M | $27.32M | $22.48M |
| SG&A | $11.29M | - | $8.27M | $8.59M | $9.97M | - | $9.58M | $6.11M | $6.88M |
| Total Operating Expenses | $41.37M | - | $38.73M | $44.41M | $47.41M | - | $38.77M | $13.30M | $29.36M |
| D&A | $351.0K | - | $300.0K | $300.0K | $501.0K | - | $300.0K | $200.0K | $482.0K |
| Operating Income | ($41.37M) | - | ($38.73M) | ($44.41M) | ($47.41M) | - | ($16.28M) | ($33.44M) | ($29.36M) |
| Interest Expense | $667.0K | - | $7.0K | $39.0K | $44.0K | - | $32.0K | $46.0K | $44.0K |
| Income Tax | - | - | - | - | - | - | - | - | - |
| Net Income | ($39.73M) | - | ($36.79M) | ($42.08M) | ($44.63M) | - | ($34.49M) | ($28.80M) | ($26.69M) |
| EPS - Basic | ($0.66) | - | ($0.85) | ($0.97) | ($1.03) | - | ($23.27) | ($0.67) | ($1.12) |
| EPS - Diluted | ($0.66) | - | ($0.85) | ($0.97) | ($1.03) | - | ($0.80) | ($0.67) | ($1.12) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.19M | $124.09M | $34.16M | $53.44M | $56.87M | $96.62M | $104.66M | $53.43M | $39.79M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $11.60M | $5.31M | $3.02M | $9.92M | $8.47M | $4.62M | $9.93M | $4.86M | $7.45M |
| Current Assets | $241.73M | $282.95M | $174.93M | $214.33M | $247.65M | $290.60M | $325.37M | $348.82M | $60.66M |
| Total Assets | $257.02M | $293.83M | $187.16M | $226.51M | $260.65M | $304.64M | $339.20M | $363.12M | $75.19M |
| Current Liabilities | $29.67M | $36.49M | $33.87M | $39.79M | $33.29M | $33.76M | $30.98M | $23.48M | $19.86M |
| Long-term Debt | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $61.44M | $61.55M | $35.21M | $42.13M | $36.65M | $38.06M | $36.49M | $29.61M | $26.02M |
| Stockholders' Equity | $195.58M | $232.28M | $151.95M | $184.38M | $224.01M | $266.59M | ($111.81M) | $333.51M | $360.99M |
| Retained Earnings | ($464.56M) | ($424.83M) | ($387.02M) | ($350.24M) | ($308.15M) | ($263.52M) | ($226.03M) | ($191.54M) | ($136.04M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($41.60M) | - | - | - | ($44.91M) | - | - | - | ($25.52M) |
| Investing Cash Flow | ($50.20M) | - | - | - | $5.58M | - | - | - | ($122.88M) |
| Financing Cash Flow | ($101.0K) | - | - | - | ($414.0K) | - | - | - | $338.05M |
| CapEx | - | - | - | - | $0 | - | - | - | $543.0K |
| Free Cash Flow | - | - | - | - | ($44.91M) | - | - | - | ($26.07M) |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||
| Gross margin | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | 1.01 | - | - | - | 0.98 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - |
| Return on assets | -15.5% | - | -19.7% | -18.6% | -17.1% | - | -10.2% | -7.9% | -35.5% |
| Return on equity | -20.3% | - | -24.2% | -22.8% | -19.9% | - | 30.8% | -8.6% | -7.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - |
| Liquidity | |||||||||
| Current ratio | 8.15 | 7.75 | 5.16 | 5.39 | 7.44 | 8.61 | 10.50 | 14.86 | 3.05 |
| Quick ratio | 8.15 | 7.75 | 5.16 | 5.39 | 7.44 | 8.61 | 10.50 | 14.86 | 3.05 |
| Cash ratio | 1.08 | 3.40 | 1.01 | 1.34 | 1.71 | 2.86 | 3.38 | 2.28 | 2.00 |
| Leverage | |||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest coverage | -62.0x | - | -5532.4x | -1138.7x | -1077.5x | - | -508.8x | -726.8x | -667.2x |
| Equity multiplier | 1.31 | 1.26 | 1.23 | 1.23 | 1.16 | 1.14 | -3.03 | 1.09 | 0.21 |
| Liabilities / Assets | 0.24 | 0.21 | 0.19 | 0.19 | 0.14 | 0.12 | 0.11 | 0.08 | 0.35 |
| Efficiency | |||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - |
| Valuation | |||||||||
| P / E | - | - | - | - | - | - | - | - | - |
| P / B | 2.7x | - | 1.7x | 0.7x | 0.4x | - | - | 1.0x | 1.6x |
| P / S | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - |
| Growth | |||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 12.7% | - | -137.9% | -32.8% | -61.5% | - | - | - | - |
| Net income growth (YoY) | 11.0% | - | -6.7% | -46.1% | -67.2% | - | - | - | - |
| EPS growth (YoY) | 35.9% | - | -6.2% | -44.8% | 8.0% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -72.3% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -12.7% | -12.9% | - | -44.7% | -37.9% | - | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Kyverna Therapeutics against the 5 most active filers in the same SIC group.